Novel treatment strategies for C3 glomerulopathy: complement blockade.

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• C3 glomerulopathy (C3G) is a rare kidney disease driven by complement alternative pathway dysregulation.
• Current treatments offer limited efficacy, with high rates of kidney failure and post-transplant recurrence.
• Existing therapies include RAS inhibitors, steroids, mycophenolic acid, and eculizumab, with variable responses.

Purpose of the Study:

• To review novel therapeutic strategies for C3 glomerulopathy.
• To focus on emerging agents targeting the complement system in C3G management.
• To provide an overview of recent advancements in C3G treatment.

Main Methods:

• Literature review of novel treatment strategies for C3G.
• Analysis of emerging agents targeting the complement system.
• Summary of recent FDA approvals for C3G therapies.

Main Results:

• Conventional treatments have limited efficacy and high C3G recurrence rates post-transplant.
• Eculizumab shows efficacy in aggressive C3G but not slowly progressive forms.
• Iptacopan and pegcetacoplan represent promising new therapeutic options, recently FDA-approved.

Conclusions:

• Novel complement-targeting agents offer improved therapeutic prospects for C3G patients.
• Iptacopan and pegcetacoplan are key advancements in C3G treatment.
• Further research is needed to fully establish the long-term efficacy and safety of new C3G therapies.